KPRX
Kiora Pharmaceuticals, Inc. NASDAQ Listed Feb 13, 2015$2.45
Mkt Cap $9.7M
52w Low $1.76
28.4% of range
52w High $4.18
50d MA $2.22
200d MA $2.34
P/E (TTM)
-0.9x
EV/EBITDA
0.0x
P/B
0.6x
Debt/Equity
0.0x
ROE
-67.2%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
-0.77
50d MA
$2.22
200d MA
$2.34
Avg Volume
508.8K
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
1371 East 2100 South · Encinitas, UT 84105 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.67 | -1.60 | -138.8% | 2.04 | +3.4% | -3.4% | -4.6% | +0.5% | +2.1% | +1.0% | — |
| Nov 7, 2025 | AMC | -0.72 | 0.01 | +101.4% | 2.33 | -0.4% | +0.0% | -1.7% | +0.9% | -5.2% | -1.4% | — |
| Aug 8, 2025 | AMC | -0.58 | -0.54 | +6.9% | 2.36 | +5.1% | +3.8% | +2.0% | -0.4% | +1.6% | +15.8% | — |
| May 9, 2025 | AMC | -0.77 | -0.52 | +32.5% | 3.25 | +1.2% | -1.8% | +0.0% | -3.1% | +1.3% | +3.2% | — |
| Mar 25, 2025 | AMC | -0.64 | -1.04 | -62.5% | 3.04 | -1.0% | -1.6% | +1.0% | +2.0% | -2.3% | -2.7% | — |
| Nov 8, 2024 | AMC | -0.90 | -0.81 | +10.0% | 3.53 | +4.0% | +5.9% | -3.2% | -5.0% | -1.2% | -3.2% | — |
| Aug 9, 2024 | AMC | -0.95 | -0.53 | +44.2% | 3.35 | -0.3% | -3.3% | -2.8% | -1.6% | +4.8% | +15.7% | — |
| May 10, 2024 | AMC | 5.58 | 3.42 | -38.7% | 4.38 | +6.8% | +4.8% | -2.0% | +3.1% | +12.7% | -1.9% | — |
| Mar 28, 2024 | AMC | -0.42 | -0.47 | -11.9% | 6.35 | -0.8% | -15.0% | -2.0% | +0.8% | -1.9% | +2.9% | — |
| Nov 9, 2023 | AMC | -2.70 | -8.01 | -196.7% | 5.84 | -4.5% | -2.4% | -4.0% | -5.1% | +0.2% | +0.2% | — |
| Aug 8, 2023 | AMC | -4.59 | -7.11 | -54.9% | 5.05 | -2.0% | -1.0% | -3.6% | +2.7% | -3.2% | +3.3% | — |
| May 9, 2023 | AMC | -1.68 | -1.00 | +40.5% | 22.77 | +0.0% | +0.8% | -0.8% | -3.2% | -4.1% | -8.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.78 | $2.75 | -1.1% | -1.8% | +2.6% | -2.5% | -1.8% | +0.4% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.02 | $3.02 | +0.0% | +2.0% | -2.3% | -2.7% | -4.1% | +0.7% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.74 | $3.70 | -1.1% | -3.2% | -5.0% | -1.2% | -3.2% | -2.1% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.11 | $4.16 | +1.2% | -10.0% | +1.9% | -2.9% | +1.9% | +0.5% |
| Jul 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.60 | $4.60 | +0.0% | +0.7% | +1.1% | +0.2% | +0.2% | -4.3% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.22 | +1.8% | +0.8% | -2.7% | -3.4% | -1.2% | +2.3% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.49 | $5.42 | -1.3% | +1.1% | +14.4% | -15.0% | -2.0% | +0.8% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.00 | $5.93 | -1.2% | +2.0% | +0.0% | -7.0% | +3.2% | -3.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.70 | $5.58 | -2.1% | -4.0% | -5.1% | +0.2% | +0.2% | -0.6% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.58 | $6.30 | +12.9% | +8.2% | -8.3% | +2.0% | +3.4% | -2.4% |
| Aug 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.63 | $4.93 | -12.4% | -16.9% | +4.9% | -2.2% | -2.5% | -7.5% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.95 | $4.95 | +0.0% | -3.2% | +3.3% | +0.0% | -1.8% | -0.6% |
| Aug 9 | Maxim Group | Maintains | Buy → Buy | — | $5.05 | $4.95 | -2.0% | -1.0% | -3.6% | +2.7% | -3.2% | +3.3% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.77 | $23.67 | +4.0% | -3.2% | -4.1% | -8.5% | +1.9% | -5.0% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.61 | $29.70 | +0.3% | +0.9% | +2.4% | +4.1% | -2.0% | -1.2% |
| Feb 9 | Maxim Group | Upgrade | Hold → Buy | — | $62.46 | $67.41 | +7.9% | -1.2% | -9.0% | -1.0% | -18.0% | +7.5% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.95 | $42.39 | +3.5% | +52.5% | -1.2% | -9.0% | -1.0% | -18.0% |
| Feb 8 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $40.95 | $42.39 | +3.5% | +52.5% | -1.2% | -9.0% | -1.0% | -18.0% |
| Aug 25 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $47.56 | $82.80 | +74.1% | +95.3% | -15.2% | +5.9% | -13.6% | -2.8% |
| Aug 15 | Maxim Group | Downgrade | Buy → Hold | — | $58.50 | $57.60 | -1.5% | -4.6% | -5.2% | -3.5% | -1.7% | -4.9% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $163.80 | $165.56 | +1.1% | -1.9% | -17.0% | +5.0% | -30.4% | -1.8% |
| Apr 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $201.60 | $207.90 | +3.1% | +3.9% | +1.1% | -4.4% | -4.4% | -3.2% |
| Jan 19 | Maxim Group | Maintains | Buy → Buy | — | $287.96 | $298.80 | +3.8% | +2.5% | -6.1% | -10.4% | +3.6% | -0.7% |
No insider trades available.
8-K · 2.02
!! High
Kiora Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Kiora Pharmaceuticals reported financial and operational results, with the full earnings release details available in the attached exhibit.
May 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A leadership transition at these biotech/pharma companies could signal strategic shifts in R&D priorities or pipeline management, potentially affecting stock valuations depending on the departing executive's role and successor's experience.
Apr 9
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
KPRX issued equity privately, likely diluting existing shareholders' ownership percentages, though the financing may provide needed capital for operations or strategic initiatives.
Apr 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kiora Pharmaceuticals' management change creates uncertainty about leadership direction and execution capability, potentially affecting investor confidence in the company's clinical pipeline and financial strategy.
Apr 2
8-K
Unknown — 8-K Filing
Kiora Pharmaceuticals advanced its retinal disease pipeline with two active Phase 2 trials, suggesting potential near-term catalysts for clinical validation and future revenue growth that could significantly impact stock valuation.
Mar 25
Data updated apr 25, 2026 5:55pm
· Source: massive.com